{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56","upperLimit":"79","value":"68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"}],"units":"Participants"}],"description":"This study used a modified version of the international criteria for neuroblastoma response. The response rate to the induction phase of the regimen and a corresponding 95% confidence interval will be calculated for all strata combined.","dispersionType":"95% Confidence Interval","groups":[{"description":"All eligible Stage 2/3, Stage 4a, and Stage 4b patients","id":"OG000","title":"All Eligible Patients"}],"paramType":"NUMBER","populationDescription":"Ineligible patients were excluded from analysis","reportingStatus":"POSTED","timeFrame":"12 weeks after participant received the first dose","title":"Response Rate to the Induction Phase of the Regimen","type":"SECONDARY","unitOfMeasure":"percentage of participants"}